Wave Life Sciences holds annual shareholder meeting
WVE•Shareholders approved an amendment increasing the shares authorized for awards under the 2021 Equity Incentive Plan by 11 million. They also re-elected all nine directors and ratified KPMG LLP as auditor for 2026.
1. Meeting approvals
At its November 12 annual meeting, Wave Life Sciences shareholders approved an amendment adding 11 million shares to the common stock authorized for awards under the Amended and Restated 2021 Equity Incentive Plan. Shareholders re-elected all nine existing directors and ratified KPMG LLP’s appointment as independent auditor for the year ending December 31, 2026.




